Clinical trial · Observational
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
Adjusted Indirect Treatment Comparison of Fruquintinib-based Therapy Versus Standard Care in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A MAIC Analysis.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric/GEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Fruquintinib | — | UNRESOLVED | — |
| Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Ramucirumab | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fruquintinib+Paclitaxel | Drug | — | UNRESOLVED |
| Ramucirumab+Paclitaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Fruquintinib + paclitaxel
- description
- Group 1: Fruquintinib + Paclitaxel (IPD)
- interventionNames
- Drug: Fruquintinib+Paclitaxel
- label
- Ramucirumab + paclitaxel
- description
- Group 2: Control Therapy (AgD from RAINBOW-Asia)
- interventionNames
- Drug: Ramucirumab+Paclitaxel
Primary outcomes (1)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- about 3 years
- description
- Time from randomization to progression/death, assessed via weighted Cox model
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed gastric/GEJ adenocarcinoma * Advanced or metastatic disease * ECOG 0-1 * Received either fruquintinib + paclitaxel or reference regimen * Available baseline characteristics for matching variables Exclusion Criteria: * Missing key outcome data * Incomplete baseline characteristics for \>2 matching variables * Prior fruquintinib exposure (control arm only)
References
Publications (1)
- DERIVEDAn N, Chen J, Li J, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Xu R, Wang F. Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. J Comp Eff Res. 2026 Aug 12:e260072. doi: 10.57264/cer-2026-0072. Online ahead of print. PMID 42583940